A Randomized, Phase III of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)
HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Hospital Wanita dan Kanak-Kanak Sabah
PRINCIPAL INVESTIGATOR
ALDRIN JASPER PLACIDUS
CONTACT
SC: Roslin Guadih
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
NAJIHAH BINTI ABU BAKAR Nurshahida Binti Mohd Nawi, Tang
CONTACT
SC: Chee Sheng
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
LEE CHEEN LENG Nur Adilah Abdul Aziz, Nur
CONTACT
SC: Syahzanani Aqilah Jami’an
Raja Permaisuri Bainun Hospital, Ipoh
PRINCIPAL INVESTIGATOR
CHAN MING JUN
CONTACT
SC: Anis Atifah Mohd Hisham
A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (DESTINY-BTC01)
Biliary Tract Cancer
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
TAN AI LIAN
CONTACT
SC: Nurin Najwa Mohd Zamri
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
CHEN MAY FENG
CONTACT
SC: Nur Aina Shafina Shafie
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
AUDI ADAWIAH BT SULAIMAN SHAH
CONTACT
SC: Nur Yasmin Muhammad Fauzi